Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data

• Published in: Eye (London) Vol. 34; no. 3; pp. 480 - 490
• Main Authors: Sadda, Srinivas R., Campbell, Joanna, Dugel, Pravin U., Holekamp, Nancy M., Kiss, Szilárd, Loewenstein, Anat, Augustin, Albert J., Shih, Vanessa, Xu, Xiaoshu, Wykoff, Charles C., Whitcup, Scott M.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.03.2020; Nature Publishing Group
• Subjects: 59; 692/698/1688/512/2613; 692/699/3161/3175; Acuity; Angiogenesis Inhibitors - therapeutic use; Diabetes; Diabetes Mellitus; Diabetic retinopathy; Diabetic Retinopathy - drug therapy; Edema; Eye; Humans; Immunotherapy; Intravitreal Injections; Laboratory Medicine; Macular Edema - drug therapy; Medicine; Medicine & Public Health; Monoclonal antibodies; Ophthalmology; Pharmaceutical Sciences/Technology; Ranibizumab - therapeutic use; Retina; Retinopathy; Surgery; Surgical Oncology; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A - therapeutic use; Visual Acuity

Background/objectives This post hoc analysis explores the relationship between residual oedema exposure after ranibizumab treatment initiation and long-term visual acuity outcome in eyes with centre-involved diabetic macular oedema (DMO). Subjects/methods Eyes randomised to the ranibizumab + prompt...